Clinical trial NCT00762190: Study of TAK-559 in Treating Subjects With Type 2 Diabetes Mellitus
Official title: A Multicenter, Double-Blind, Placebo-Controlled, Randomized Study of the Safety of TAK-559 in the Treatment of Patients With Type 2 Diabetes Mellitus
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: PHASE3
Conditions: Diabetes Mellitus
Keywords: Glucose Metabolism Disorder
Dysmetabolic Syndrome
Type II Diabetes
Diabetes Mellitus, Lipoatrophic
Dyslipidemia
Drug Therapy
Lead sponsor: Takeda
Sponsor class: INDUSTRY
First posted: 2008-09-30
Enrollment: 348
Sex: ALL
Minimum age (years): 25
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of this study was to determine the safety of TAK-559, once daily (QD), in treating subjects receiving a stable dose of insulin to control type 2 diabetes mellitus.

Detailed description: Insulin is a primary regulator of blood glucose concentrations. A subnormal response to circulating insulin levels at target tissues leads to a decrease in insulin-mediated glucose uptake. Insulin resistance is associated with normal to high insulin levels and is often accompanied by dyslipidemia, a disruption in lipid metabolism resulting in increased triglycerides and low-density lipoprotein levels as well as decreased high-density lipoprotein levels in patients with type 2 diabetes mellitus. In the early stages of insulin resistance, a compensatory mechanism of increased insulin secretion by the pancreas maintains normal to near-normal glucose levels. Once the pancreas fails to maintain the increased insulin output, overt type 2 diabetes mellitus occurs.

Insulin also plays an important role in the metabolism of fat and proteins and exerts its influence at the peroxisome proliferator-activated receptor level. Peroxisome proliferator-activated receptor -alpha receptors are expressed predominantly in skeletal muscle, adipose tissue, heart, liver, kidney, gut, macrophages, and vascular tissue, and play a key role in energy storage, glucose homeostasis, and vascular biology. Thus, as insulin activates peroxisome proliferator-activated receptor-alpha receptors, this results in the cellular uptake of glucose. Peroxisome proliferator-activated receptor receptors are ligand-activated transcription elements that regulate gene expression necessary for metabolism. For this reason, peroxisome proliferator-activated receptors play a pivotal role in glucose homeostasis, adipocyte differentiation, and lipid storage. The genes predominantly targeted by transcription activity of activated peroxisome proliferator-activated receptor-alpha receptors are those that mediate fatty acid uptake, fatty acid oxidation, and lipoprotein metabolism. As such, peroxisome proliferator-activated receptor-alpha agonists have their greatest effect on lipid metabolism and vascular biology.

TAK-559 is a novel oxyiminoalkanoic acid under investigation for use as an oral agent in the treatment of patients with type 2 diabetes mellitus. TAK-559 has partial peroxisome proliferator-activated receptor-alpha agonist activity, potent peroxisome proliferator-activated receptor-alpha activity, and modest peroxisome proliferator-activated receptor-gamma activity at high concentrations in nonclinical models.

This study was designed to evaluate the safety of TAK-559 in the treatment of patients with type 2 diabetes mellitus who were on a stable dose of insulin.

Eligibility criteria: Inclusion Criteria:

* Had type 2 diabetes mellitus using American Diabetes Association diagnostic criteria, currently treated with insulin therapy.
* Required sponsor approval if older than 65 years.
* Had a Screening glycosylated hemoglobin less than or equal to 8.0%.
* Had a Screening fasting plasma glucose less than or equal to 200 mg/dL (11.1 mmol/L).
* Had a Screening low density lipoprotein less than or equal to 160 mg/dL (4.1 mmol/L).
* Had a Screening thyroid stimulating hormone level less than or equal to 5.5 μU/mL (5.5 μU/L) and greater than or equal to 0.35 μU/mL (0.35 μU/L).
* Was willing to continue dietary counseling during study and had dietary advice greater than or equal to 2.5 months prior to Screening.
* Had a Screening ejection fraction greater than or equal to 40% from echocardiogram.
* Had a Screening blood pressure less than or equal to 140/95 mm Hg.
* Was willing to perform daily self-monitoring blood glucose tests.
* A female subject of childbearing potential who was sexually active agreed to use adequate contraception, and was neither pregnant nor lactating from Screening throughout the duration of the study.
* Was in good health as determined by physician (via medical history and physical examination) other than having type 2 diabetes mellitus.
* Had clinical laboratory evaluations within normal reference range or deemed not clinically significant by the investigator or sponsor.
* Started insulin therapy at least 3 months prior to Randomization.

Exclusion Criteria:

* Had a hypersensitivity to peroxisome proliferator-activated receptor -alpha or gamma agonists, thiazolidinediones, or fibrates.
* Was diagnosed with type 1 diabetes mellitus or hemochromatosis, or had a history of ketoacidosis.
* Required greater than 2 hypertension medications to achieve adequate blood pressure control.
* Had a history of coronary angioplasty or bypass graft, or unstable angina pectoris within 1 year of Screening.
* Had a history of myocardial infarction.
* Had a history of transient ischemic attack or documented cerebrovascular accident within 6 months of Screening.
* Abdominal, thoracic, or vascular surgery within 6 months of Screening warranting exclusion (investigator's opinion).
* Had a screening creatine phosphokinase value greater than 3 times the upper limit of normal.
* Had persistent unexplained microscopic or macroscopic hematuria or history of bladder cancer.
* Had a screening triglyceride level greater than 500 mg/dL (5.6 mmol/L).
* Experienced a change in allowed lipid-lowering medication (dose or drug) within 2 months of Randomization.
* Experienced a change in blood pressure medication (dose or drug) within 1 month of Randomization.
* Had systemic corticosteroids within 1 month of Randomization.
* Had donated or received blood products within 3 months of Randomization.
* Had a condition known to invalidate glycosylated hemoglobin.
* Had a history of drug abuse or alcohol abuse within 2 years.
* Had a significant cardiovascular disease, including New York Heart Association Functional (Cardiac) Classification II, III or IV.
* Had a Screening B-Type Natriuretic Peptide greater than 100 pg/mL (100 ng/L).
* Had a history of left ventricular hypertrophy (women greater than 110 g/m2 and men greater than 134 g/m2).
* Had a clinically significant mitral insufficiency at Screening.
* Had a clinically significant aortic stenosis at Screening.
* Had a Screening body mass index greater than 45.
* Had a history of cancer with no remission within 5 years of Randomization, other than basal cell or stage 1 squamous cell carcinoma of the skin.
* Had an alanine transaminase or aspartate transaminase level greater than 3 times the upper limit of normal, active liver disease or jaundice at Screening.
* Had a positive human immunodeficiency virus, hepatitis B surface antigen, or hepatitis B e antigen test at Screening.
* Was required to take or intended to continue taking any disallowed medication, prescription medication, herbal treatment or over-the counter medication that may interfered with the evaluation of the study medication, including:

  * oral antidiabetic agents (including sulfonylureas, alpha-glucosidase inhibitors, thiazolidinediones, peroxisome proliferator-activated receptor agonists and metformin)
  * fibrates
  * systemic corticosteroids
  * warfarin
  * rifampin
  * nicotinic acid
  * minoxidil
  * hydralazine
  * St. John's Wort
* Was participating or had participated in an investigational study within the past 30 days.
* Had a serious disease or condition at Screening or Randomization that could affect life expectancy or made it difficult to manage/follow patient according to protocol.

Primary outcomes:
measure: Incidence of Adverse events.
timeFrame: All visits or at occurrence.
measure: Clinical safety lab tests.
timeFrame: Weeks 12, 24, and Final Visit.
measure: 12-lead electrocardiogram.
timeFrame: Weeks: 24 and Final Visit.
measure: Urinalysis.
timeFrame: Weeks: 12, 24, 36, 48 and Final Visit.
measure: Change from Baseline in Blood pressure and pulse.
timeFrame: At all visits.
measure: Change from Baseline in Body weight.
timeFrame: At all visits.
measure: Left ventricular mass index by body surface area measured by echocardiogram.
timeFrame: Weeks: 24 and Final Visit.
Secondary outcomes:
measure: Change from Baseline in total daily dose of insulin.
timeFrame: At all visits.
measure: Change from Baseline in triglycerides.
timeFrame: Weeks: 24 and Final Visit.
measure: Change from Baseline in cholesterol.
timeFrame: Weeks 24 and Final Visit
measure: Change from Baseline in total, high-density lipoproteins.
timeFrame: Weeks: 24 and Final Visit.
measure: Change from Baseline in low-density lipoproteins.
timeFrame: Weeks 24 and Final Visit
measure: Change from Baseline in low-density lipoprotein fractionation.
timeFrame: Weeks 24 and Final Visit
measure: Change from Baseline in very low-density lipoprotein.
timeFrame: Weeks 24 and Final Visit
measure: Change from Baseline in free fatty acids.
timeFrame: Weeks 24 and Final Visit
measure: Change from Baseline in apolipoproteins (AI, B).
timeFrame: Weeks 24 and Final Visit
Other outcomes:
Locations:
Study officials:
affiliation: Takeda
name: VP Biological Sciences
role: STUDY_DIRECTOR
References: